Spondylitis News and Research

RSS

Reduced rheumatoid arthritis risk in schizophrenia linked to underreporting

People with a history of schizophrenia appear to have a lower risk of developing rheumatoid arthritis than the general population, but the association may be due to underreporting, say researchers.

16 Apr 2014

Mechanical circulatory assist device may have untapped potential in heart surgery patients, say physicians

The most frequently used mechanical circulatory assist device in the world may have untapped potential, physicians say.

31 Mar 2014

POZEN reports total revenue of $4.7 million for fourth quarter 2013

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the fourth quarter and year ended December 31, 2013.

5 Mar 2014

Alvogen launches Inflectra into Central and Eastern Europe

Alvogen, the multinational pharmaceuticals company, today announced the launch of Inflectra (Infliximab) into Central and Eastern Europe. Inflectra, Europe's first biosimilar monoclonal antibody (mAb) therapy that has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

13 Feb 2014

Women taking immunosuppressive medications during pregnancy do not put their babies at risk

Women with chronic autoimmune diseases who take immunosuppressive medications during their first trimester of pregnancy are not putting their babies at significantly increased risk of adverse outcomes, according to a Vanderbilt study released online by the journal Arthritis and Rheumatism.

11 Nov 2013

Anti-tumor necrosis factor drugs modestly reduce risk of acute coronary syndrome

Tumor necrosis factor inhibitor drugs (commonly called Anti-TNFs) modestly reduce the risk of acute coronary syndrome, such as heart attacks and angina, in rheumatoid arthritis patients whose inflammation places them at higher risk of developing coronary heart disease, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.

7 Oct 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis.

30 Sep 2013

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira, the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) approval of Inflectra™ (infliximab), Europe's first biosimilar monoclonal antibody (mAb) therapy. Inflectra has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

10 Sep 2013

Baxter, Coherus Ink Biosimilar Collaboration Worth Up To $246M

...

3 Sep 2013

Compatibility gene may influence finding life partner as well as our health, individuality

A University of Manchester professor and his wife have had their own DNA analysed for compatibility as part of the research for a new book out on 1 October in the US and next week in the UK.

From The University of Manchester 26 Aug 2013

Novel antibody biomarkers could significantly improve diagnosis in RA, study shows

Data presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, show that novel antibody biomarkers could significantly improve diagnosis in rheumatoid arthritis.

14 Jun 2013

Using Swiss ball improves walking performance and muscle strength in AS patients

A new study presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrates that progressive muscle strengthening using a Swiss ball is effective in improving muscle strength and walking performance in patients with Ankylosing Spondylitis (AS).

13 Jun 2013

University of Oxford researchers receive grant to study genes that contribute to ankylosing spondylitis

A team at the University of Oxford has received a grant of £160,000 from Arthritis Research UK to study the function of the genes which contribute to people developing a painful inflammatory back condition called ankylosing spondylitis.

13 Jun 2013

Simponi injection gets FDA approval to treat adults with ulcerative colitis

The U.S. Food and Drug Administration today approved a new use for Simponi (golimumab) injection to treat adults with moderate to severe ulcerative colitis.

16 May 2013

POZEN announces revenue of $1.4 million for first quarter 2013

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the first quarter ended March 31, 2013.

8 May 2013

Study: Use of anti-TNF therapies in RA patients does not increase risk of herpes zoster

Patients with rheumatoid arthritis (RA) who initiated use of anti-tumor necrosis factor therapies were not at a higher risk of developing herpes zoster (shingles), compared with patients who initiated nonbiologic treatment regimens, according to research from the University of Alabama at Birmingham (UAB) and the Oregon Health and Science University. The findings appeared in the March 6, 2013, issue of the Journal of the American Medical Association (JAMA).

22 Apr 2013

Researchers unravel dual role of tumor necrosis factor in TB

Tumor necrosis factor - normally an infection-fighting substance produced by the body- can actually heighten susceptibility to tuberculosis if its levels are too high.

12 Apr 2013

RA patients who initiate anti-TNF therapies do not have higher risk of shingles: Study

Although patients with rheumatoid arthritis have a disproportionately higher incidence of herpes zoster (shingles), an analysis that included nearly 60,000 patients with RA and other inflammatory diseases found that those who initiated anti-tumor necrosis factor therapies were not at higher risk of herpes zoster compared with patients who initiated nonbiologic treatment regimens, according to a study appearing in the March 6 issue of JAMA.

7 Mar 2013